Now that the GDPR deadline of May 25 has come and gone, many life sciences companies will have come to realise that GDPR compliance is not simply a legal problem or an IT project, but an enterprise
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh